Verapamil-d3 (hydrochloride)

Verapamil-d3 (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±) -Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].

Product Specifications

CAS Number

[2714485-49-9]

Product Name Alternative

(±) -Verapamil-d3 (hydrochloride) ; CP-16533-1-d3 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H301

Target

Calcium Channel; Cytochrome P450; Isotope-Labeled Compounds; P-glycoprotein

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Field of Research

Cardiovascular Disease

Purity

99.57

Solubility

10 mM in DMSO|H2O : 50mg/mL (ultrasonic)

Smiles

[H]Cl.COC1=CC=C(C(C#N)(C(C)C)CCCN(CCC2=CC=C(OC)C(OC)=C2)C([2H])([2H])[2H])C=C1OC

Molecular Formula

C27H36D3ClN2O4

Molecular Weight

494.08

Precautions

H301

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Krikler DM. Verapamil in arrhythmia. Br J Clin Pharmacol. 1986;21 Suppl 2:183S-189S.|[3]Rehnqvist N, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) . Eur Heart J. 1996 Jan;17 (1) :76-81.|[4]Kubo Y, et al. Blood-to-Retina Transport of Fluorescence-Labeled Verapamil at the Blood-Retinal Barrier. Pharm Res. 2018 Mar 12;35 (5) :93.|[5]Gowarty JL, et al. Verapamil as a culprit of palbociclib toxicity. J Oncol Pharm Pract. 2019 Apr;25 (3) :743-746.|[6]Zhou P, et al. Anti-arrhythmic effect of Verapamil is accompanied by preservation of cx43 protein in rat heart. PLoS One. 2013 Aug 12;8 (8) :e71567.